Generic placeholder image

Current Pharmaceutical Design

Author(s): Shweta Ramkar, Abhishek K. Sah, Nagendra Bhuwane, Ishwari Choudhary, Narayan Hemnani and Preeti K. Suresh*

DOI: 10.2174/1381612826666200515133142

DownloadDownload PDF Flyer Cite As
Nano-Lipidic Carriers as a Tool for Drug Targeting to the Pilosebaceous Units

Page: [3251 - 3268] Pages: 18

  • * (Excluding Mailing and Handling)

Explore Articles
About Journal
For Authors
For Editors
For Reviewers

Abstract

The pilosebaceous unit is the triad comprising of hair follicle, arrector pilli muscle, and sebaceous gland. Drug delivery to and through the hair follicles has garnered much attention of the researchers and the hair follicles represent an attractive target site via topical applications. They are bordered by capillaries and antigenpresenting cells, connected to the sebaceous glands and the bulge region of the hair follicle anchors the stem cells. The nano lipid carriers have the propensity to penetrate through the skin via transcellular route, intracellular route and follicular route. It has been established that nano lipid carriers have the potential for follicular drug delivery and provide some advantages over conventional pathways, including improved bioavailability, enhanced penetration depth, fast transport into the skin, tissue targeting and form a drug reservoir for prolonged release. This review describes the pilosebaceous unit (PSU) and related diseases and the recent lipid-based nanotechnology approaches for drug delivery to the follicular unit as well as related issues. Different types of nano lipid carriers, including ethosomes, liposomes, nanoparticles, solid lipid nanoparticles (SLNs), and nano lipid carriers (NLCs) have been reported for follicular drug delivery. Targeted drug delivery with nano-lipid carriers has the potential to augment the efficacy of drugs/bioactives to treat diseases of PSU. This review systematically introduces the activities of different formulations and the use of nano lipid carriers in treating PSU related disorders like alopecia, acne, and hirsutism.

Keywords: Hair follicles, skin, lipids, nanocarrier, drug delivery, topical, skin disease, targeting.

[1]
Cevc G, Vierl U. Nanotechnology and the transdermal route. A state of the art review and critical appraisal. J Control Rel 2010; 141: 277-99.
[http://dx.doi.org/10.1016/j.jconrel.2009.10.016]
[2]
Niemann C, Horsley V. Development and homeostasis of the sebaceous gland. Semin Cell Dev Biol 2012; 23: 928-36.
[http://dx.doi.org/10.1016/j.semcdb.2012.08.010]
[3]
Escobar-Morreale HF, Carmina E, Dewailly D, et al. Epidemiology, diagnosis and management of hirsutism: A consensus statement by the androgen excess and polycystic ovary syndrome society. Hum Reprod Update 2012; 18: 146-70.
[http://dx.doi.org/10.1093/humupd/dmr042]
[4]
Makrantonaki E, Ganceviciene R, Zouboulis C. An update on the role of the sebaceous gland in the pathogenesis of acne. Dermatoendocrinol 2011; 3: 41-9.
[http://dx.doi.org/10.4161/derm.3.1.13900]
[5]
Haffner M. Structure and function of pilosebaceous units on the heads of small mammals (Insectivora, Chiroptera, Rodentia). Acta Zoologica 2000; 81: 195-203.
[http://dx.doi.org/10.1046/j.1463-6395.2000.00049.x]
[6]
Raber AS, Mittal A, Schäfer J, et al. Quantification of nanoparticle uptake into hair follicles in pig ear and human forearm. J Control Rel 2014; 179: 25-32.
[http://dx.doi.org/10.1016/j.jconrel.2014.01.018]
[7]
Lademann J, Knorr F, Richter H, et al. Hair follicles as a target structure for nanoparticles. J Innov Opt Health Sci 2015; 8: 1-8.
[http://dx.doi.org/10.1142/S1793545815300049]
[8]
Wosicka H, Cal K. Targeting to the hair follicles: Current status and potential. J Dermatol Sci 2010; 57: 83-9.
[http://dx.doi.org/10.1016/j.jdermsci.2009.12.005]
[9]
Planz V, Lehr CM, Windbergs M. In vitro models for evaluating safety and efficacy of novel technologies for skin drug delivery. J Control Release 2016; 242: 89-104.
[http://dx.doi.org/10.1016/j.jconrel.2016.09.002]
[10]
Roberts MS, Mohammed Y, Pastore MN, et al. Topical and cutaneous delivery using nanosystems. J Control Release 2017; 247: 86-105.
[http://dx.doi.org/10.1016/j.jconrel.2016.12.022]]
[11]
Jain SK, Verma A, Jain A, Hurkat P. Transfollicular drug delivery: current perspectives. Research and Reports in Transdermal Drug Delivery 2016; 5: 1-17.
[http://dx.doi.org/10.2147/RRTD.S75809]
[12]
Vogt A, Wischke C, Neffe AT, et al. Nanocarriers for drug delivery into and through the skin - Do existing technologies match clinical challenges? J Control Release 2016; 242: 3-15.
[http://dx.doi.org/10.1016/j.jconrel.2016.07.027]
[13]
Alexander A, Dwivedi S, Ajazuddin , et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release 2012; 164: 26-40.
[http://dx.doi.org/10.1016/j.jconrel.2012.09.017]
[14]
Galbraith H. Fundamental hair follicle biology and fine fibre production in animals. Animal 2010; 4: 1490-509.
[http://dx.doi.org/10.1017/S175173111000025X]
[15]
Singh P, Sihorkar V, Jaitely V, et al. Pilosebaceous unit : Anatomical considerations and drug delivery opportunities. Ind J Pharmacol 2000; 32: 269-81.
[16]
Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 2016; 74: 945-73.
[http://dx.doi.org/10.1016/j.jaad.2015.12.037]
[17]
Mak WC, Patzelt A, Richter H, et al. Triggering of drug release of particles in hair follicles. J Control Rel 2012; 160: 509-14.
[http://dx.doi.org/10.1016/j.jconrel.2012.04.007]
[18]
Riaz N, Wolden SL, Gelblum DY, Eric J. Deregulation of STING signaling in colorectal carcinoma constrains DNA-Damage responses and correlates with tumorigenesis. HHS Public Access 2016; 118: 6072-8.
[19]
Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatol 2001; 203: 277-9.
[http://dx.doi.org/10.1159/000051771]
[20]
Wille JJ, Kydonieus A. Palmitoleic acid isomer (C16:1∆6) in human skin sebum is effective against gram-positive bacteria. Skin Pharmacol Appl Skin Physiol 2003; 16: 176-87.
[http://dx.doi.org/10.1159/000069757]
[21]
Zouboulis CC, Seltmann H, Hiroi N, et al. Corticotropin-releasing hormone: An autocrine hormone that promotes lipogenesis in human sebocytes. P NAS 2002; 99: 7148-53.
[22]
Thiboutot D, Gilliland K, Cong Z, et al. Human skin is a steroidogenic tissue: Steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol 2003; 120: 905-14.
[http://dx.doi.org/10.1046/j.1523-1747.2003.12244.x]
[23]
Böhm M, Schiller M, Ständer S, et al. Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol 2002; 118: 533-9.
[http://dx.doi.org/10.1046/j.0022-202x.2001.01704.x]
[24]
Ford SJ, Bigliardi PL, Sardella TCP, et al. Structural and functional analysis of intact hair follicles and pilosebaceous units by volumetric multispectral optoacoustic tomography. J Invest Dermatol 2016; 136: 753-61.
[http://dx.doi.org/10.1016/j.jid.2015.09.001]
[25]
Marks DH, Penzi LR, Ibler E, et al. The medical and psychosocial associations of alopecia: Recognizing hair loss as more than a cosmetic concern. Am J Clin Dermatol 2019; 20: 195-200.Available from:.
[http://dx.doi.org/10.1007/s40257-018-0405-2]]
[26]
Tamanekar R, Salavkar S, Athawale R. Pilosebaceous targeting – An emerging concept in topical and cosmetic science. Res J Topic Cosmet Sci 2011; 2: 45-51.
[27]
Kealey T, Philpott M, Guy R. The regulatory biology of the human pilosebaceous unit. Baillieres Clinic Obstet Gynaecol 1997; 11: 205-27.
[http://dx.doi.org/10.1016/S0950-3552(97)80034-X]
[28]
Patzelt A, Lademann J. Drug delivery to hair follicles. Expert Opinion Drug Deliv 2013; 10: 787-97.
[http://dx.doi.org/10.1517/17425247.2013.776038]
[29]
Ramos-e-Silva M, Pirmez R. Disorders of hair growth and the pilosebaceous unit: Facts and controversies. Clin Dermatol 2013; 31: 759-63.
[http://dx.doi.org/10.1016/j.clindermatol.2013.06.003]
[30]
Ana Paula. Types of acne and associated therapy: A review. Am Res J Pharm 2016; pp. 1-9.
[http://dx.doi.org/10.21694/2380-5706.16001]
[31]
Seiffert K, Seltmann H, Fritsch M, Zouboulis CC. Inhibition of 5α-reductase activity in SZ95 sebocytes and HaCaT keratinocytes in vitro. Hormone Metabole Res 2007; 02: 141-8.
[http://dx.doi.org/10.1055/s-2007-961814]
[32]
Rosenfield RL, Deplewski D. Role of androgens in the developmental biology of the pilosebaceous unit. Am J Med 1995; 98: S80-8.
[33]
Qidwai A, Pandey M, Pathak S, et al. The emerging principles for acne biogenesis: A dermatological problem of puberty. Human Microbiome Journal 2017; 4: 7-13.
[http://dx.doi.org/10.1016/j.humic.2017.05.001]
[34]
Lynn DD, Umari T, Dunnick CA, Dellavalle RP. The epidemiology of acne vulgaris in late adolescence. Adolesc Health Med Ther 2016; 7: 13-25.
[http://dx.doi.org/10.2147/AHMT.S55832]
[35]
Natural Hair Growth. Health4sure, Cardiff, United Kingdom, 2018.https://www.health4sure.co.uk/5-natural-ways-you-can-prevent unwanted hair-fall-and-natural-hair-growth/ (accessed June 28, 2019)
[36]
Patwekar SL, Pedewad SR, Gattani S. Development and evaluation of nanostructured lipid carriers-based gel of isotretinoin. Particul Sci Technol 2018; 36: 832-43.
[http://dx.doi.org/10.1080/02726351.2017.1305026]
[37]
Cong T-X, Hao D, Wen X, et al. From pathogenesis of acne vulgaris to anti-acne agents. Arch Dermatol Res 2019; 311: 337-49.
[http://dx.doi.org/10.1007/s00403-019-01908-x]
[38]
Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol 2018; 4: 56-71.
[http://dx.doi.org/10.1016/j.ijwd.2017.10.006]
[39]
Islam N, Leung PSC, Huntley AC, Gershwin ME. The autoimmune basis of alopecia areata: A comprehensive review. Autoimmun Rev 2015; 14: 81-9.
[http://dx.doi.org/10.1016/j.autrev.2014.10.014]
[40]
Soni VK. Androgenic alopecia: A counterproductive outcome of the anabolic effect of androgens. Med Hypotheses 2009; 73: 420-6.
[http://dx.doi.org/10.1016/j.mehy.2009.03.032]
[41]
Dey-Rao R, Sinha AA. A genomic approach to susceptibility and pathogenesis leads to identifying potential novel therapeutic targets in androgenetic alopecia. Genomics 2017; 109: 165-76.
[http://dx.doi.org/10.1016/j.ygeno.2017.02.005]
[42]
Roque LV, Dias IS, Cruz N, et al. Design of finasteride-loaded nanoparticles for potential treatment of alopecia. Skin Pharmacol Physiol 2017; 30: 197-204.
[43]
Gordon K, Gordon K, Tosti A. Alopecia: evaluation and treatment. Clin Cosmet Investig Dermatol 2011; 4: 101-6.
[http://dx.doi.org/10.2147/CCID.S10182]]
[44]
Hiipakka RA, Liao S. Molecular mechanism of androgen action. Trends Endocrinol Metabol 1998; 9: 317-24.
[http://dx.doi.org/10.1016/S1043-2760(98)00081-2]
[45]
Cauci S, Chiriacò G, Cecchin E, et al. Androgen receptor (AR) gene (CAG)n and (GGN)n length polymorphisms and symptoms in young males with long-lasting adverse effects after finasteride use against androgenic alopecia. Sex Med 2017; 5: e61-71.
[http://dx.doi.org/10.1016/j.esxm.2016.11.001]
[46]
Ramos PM. Female pattern hair loss : A clinical and pathophysiological review 2015; 90: 529-43..
[47]
Rinaldi S, Bussa M, Mascaro A. Update on the treatment of androgenetic alopecia. Eur Rev Med Pharmacol Sci 2016; 20: 54-8.
[48]
Sathishkumar P, Preethi J, Vijayan R, et al. Anti-acne, anti-dandruff and anti-breast cancer efficacy of green synthesised silver nanoparticles using Coriandrum sativum leaf extract. J Photochem Photobiology B: Biology 2016; 163: 69-76.
[http://dx.doi.org/10.1016/j.jphotobiol.2016.08.005]
[49]
Wiesmann N, Kluenker M, Demuth P, et al. Zinc overload mediated by zinc oxide nanoparticles as innovative anti-tumor agent. J Trace Elem Med Biol 2019; 51: 226-34.
[http://dx.doi.org/10.1016/j.jtemb.2018.08.002]
[50]
Vyas A, Sonker AK, Gidwani B. Carrier-based drug delivery system for treatment of acne. The ScientificWorldJournal 2014; 2014: 1-14.
[51]
Patzelt A, Knorr F, Blume-Peytavi U, et al. Hair follicles, their disorders and their opportunities. Drug Discov Today Dis Mech 2008; 5: 173-81.
[http://dx.doi.org/10.1016/j.ddmec.2008.04.006]
[52]
Touitou E, Dayan N, Bergelson L, et al. Ethosomes - Novel vesicular carriers for enhanced delivery: Characterization and skin penetration properties. J Control Rel 2000; 65: 403-18.
[http://dx.doi.org/10.1016/S0168-3659(99)00222-9]
[53]
Nainwal N, Jawla S, Singh R, Saharan VA. Transdermal applications of ethosomes–a detailed review. J Liposome Res 2019; 29: 103-13.
[http://dx.doi.org/10.1080/08982104.2018.1517160]
[54]
Rao Y, Zheng F, Zhang X, et al. In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS PharmSciTech 2008; 9: 860-5.
[http://dx.doi.org/10.1208/s12249-008-9124-y]
[55]
Honary S, Ebrahimi P, Nikbakht M. Optimization of finasteride nano-emulsion preparation using chemometric approach. Trop J Pharm Res 2013; 12: 457-60.
[http://dx.doi.org/10.4314/tjpr.v12i4.2]
[56]
Kohli AK, Alpar HO. Potential use of nanoparticles for transcutaneous vaccine delivery: Effect of particle size and charge. Int J Pharm 2004; 275: 13-7.
[http://dx.doi.org/10.1016/j.ijpharm.2003.10.038]
[57]
Cevc G, Blume G. New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers, Transfersomes. Biochim Biophys Acta Biomembranes 2001; 1514: 191-205.
[http://dx.doi.org/10.1016/S0005-2736(01)00369-8]
[58]
Sujatha S, Sowmya G, Chaitanya M, et al. Preparation, characterization and evaluation of finasteride ethosomes. Int J Drug Del Technol 2016; 8: 01-11..
[59]
Wilson V, Siram K, Rajendran S, Sankar V. Development and evaluation of finasteride loaded ethosomes for targeting to the pilosebaceous unit. Artif Cells Nanomed Biotechnol 2018; 46: 1892-901.
[http://dx.doi.org/10.1080/21691401.2017.1396221]
[60]
Jain B, Singh B, Katare OP, Vyas SP. Development and characterization of minoxidil-loaded liposomal system for delivery to pilosebaceous units. J Liposome Res 2010; 20: 105-14.
[http://dx.doi.org/10.3109/08982100903161449]
[61]
Foldvari M, Faulkner G, Mezei C, Mezei M. Interaction of liposomal drug delivery systems with cells and tissues: Microscopic studies. Cells and Materials 1992; 2: 8.
[62]
Betz G, Imboden R, Imanidis G. Interaction of liposome formulations with human skin in vitro. Int J Pharm 2001; 229: 117-29.
[http://dx.doi.org/10.1016/S0378-5173(01)00824-9]
[63]
Khan MZU, Khan SA, Ubaid M, et al. Finasteride topical delivery systems for androgenetic alopecia. Curr Drug Deliv 2018; 15: 1100-11.
[http://dx.doi.org/10.2174/1567201815666180124112905]
[64]
Fluhr JW, Barsom O, Gehring W, Gloor M. Antibacterial efficacy of benzoyl peroxide in phospholipid liposomes. Dermatol 1999; 198: 273-7.
[http://dx.doi.org/10.1159/000018129]
[65]
Abdulridha RS, Hashim HA, Kadhim AH, et al. Effect of method of preparation on physical properties of ciprofloxacin HCL elastic liposomes intended to be utilized in treatment of acne vulgaris. Int J Res Ayurveda Pharm 2013; 4: 742-6.
[http://dx.doi.org/10.7897/2277-4343.04524]
[66]
Bhalerao SS, Harshal AR. Preparation, optimization, characterization, and stability studies of salicylic acid liposomes. Drug Dev Ind Pharm 2003; 29: 451-67.
[http://dx.doi.org/10.1081/DDC-120018380]
[67]
Li L, Lishko V, Hoffman RM. Liposome Targeting of high molecular weight DNA to the hair follicles of histocultured skin : a model for gene therapy of the hair growth processes. In Vitro Cell Dev Biol 1993; 29A: 258-60.
[68]
Lieb LM, Flynn G, Weiner N. Follicular (pilosebaceous unit) deposition and pharmacological behavior of cimetidine as a function of formulation. Pharm Res 1994; 11: 1419-23.
[http://dx.doi.org/10.1023/A:1018939805601]
[69]
Hoffman RM. Topical liposome targeting of dyes, melanins, genes, and proteins selectively to hair follicles. J Drug Target 1998; 5: 67-74.
[http://dx.doi.org/10.3109/10611869808995860]
[70]
Aldhalimi MA, Hadi NR, Ghafil FA. Promotive effect of topical ketoconazole, minoxidil, and minoxidil with tretinoin on hair growth in male mice. ISRN Pharmacol 2014; 1-5.
[http://dx.doi.org/10.1155/2014/575]
[71]
Sinha P, Srivastava S, Mishra N, Yadav NP. New perspectives on antiacne plant drugs: Contribution to modern therapeutics. BioMed Res Int 2014; 1-19.
[http://dx.doi.org/10.1155/2014/301304]
[72]
Taub AF, Schieber AC. Photodynamic therapy for acne vulgaris and sebaceous gland Hyperplasia.Gold MH (ed): Cosmetic Photodynamic Therapy Aesthet Dermatol Basel, Karger,. 2016; vol 3: pp. 85-102.
[http://dx.doi.org/10.1159/000439341]
[73]
Li L, Lishko VK, Hoffman RM. Liposomes can specifically target entrapped melanin to hair follicles in histocultured skin. In Vitro Cell Dev Biol Animal 1993; 29: 192-4.
[http://dx.doi.org/10.1007/BF02634181]
[74]
Skalko N, Cajkovac M, Jalsenjak I. Liposomes with clindamycin hydrochloride in the therapy of acne vulgaris. Int J Pharm 1992; 85: 97-101.
[http://dx.doi.org/10.1016/0378-5173(92)90138-R]
[75]
Tabbakhian M, Tavakoli N, Jaafari MR, Daneshamouz S. Enhancement of follicular delivery of finasteride by liposomes and niosomes: 1.In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm 2006; 323: 1-10.
[http://dx.doi.org/10.1016/j.ijpharm.2006.05.041]
[76]
Lee IA, Maibach HI. Pharmionics in dermatology: A review of topical medication adherence. Am J Clin Dermatol 2006; 7: 231-6.
[http://dx.doi.org/10.2165/00128071-200607040-00004]
[77]
Vogt A, Mandt N, Lademann J, Schaefer H, Blume-Peytavi U. Follicular targeting - a promising tool in selective dermatotherapy. J Investig Dermatol Symp Proc 2005; 10: 252-5.
[http://dx.doi.org/10.1111/j.1087-0024.2005.10124.x]
[78]
Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume-Peytavi U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol 2004; 123: 168-76.
[http://dx.doi.org/10.1111/j.0022-202X.2004.22717.x]
[79]
Castro GA, Ferreira LAM. Novel vesicular and particulate drug delivery systems for topical treatment of acne. Exp Opin Drug Del 2008; 5: 665-79.
[http://dx.doi.org/10.1517/17425247.5.6.665]
[80]
Rolland A, Wagner N, Chatelus A, Shroot B, Schaefer H. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res 1993; 10: 1738-44.
[http://dx.doi.org/10.1023/A:1018922114398]
[81]
Chandrashekha BS, Anitha M, Ruparelia M, et al. Tretinoin nanogel 0.025% versus conventional gel 0.025% in patients with acne vulgaris: A randomized, active controlled, multicentre, parallel group, Phase IV clinical trial. J Clin Diagn Res 2015; 9: 4-9.
[http://dx.doi.org/10.7860/JCDR/2015/10663.5469]
[82]
Abd E, Benson HAE, Roberts MS, Grice JE. Minoxidil skin delivery from nanoemulsion formulations containing eucalyptol or oleic acid: Enhanced diffusivity and follicular targeting. Pharmaceutics 2018; 10: 1-12.
[http://dx.doi.org/10.3390/pharmaceutics10010019]
[83]
Kumar A, Kushwaha V, Sharma PK. Pharmaceutical microemulsion: Formulation, characterization and drug deliveries across skin. Int J Drug Dev Res 2014; 6: 1-21.
[84]
Madheswaran T, Baskaran R, Thapa RK, et al. Design and in vitro evaluation of finasteride-loaded liquid crystalline nanoparticles for topical delivery. AAPS PharmSciTech 2013; 14: 45-52.
[http://dx.doi.org/10.1208/s12249-012-9888-y]
[85]
Mathes C, Melero A, Conrad P, et al. Nanocarriers for optimizing the balance between interfollicular permeation and follicular uptake of topically applied clobetasol to minimize adverse effects. J Control Rel 2016; 223: 207-14.
[http://dx.doi.org/10.1016/j.jconrel.2015.12.010]
[86]
Główka E, Wosicka-fra H. Polymeric nanoparticles-embedded organogel for roxithromycin delivery to hair follicles. Eur J Pharm Biopharm 2014; 88: 75-84.
[87]
Das L, Kaurav M, Pandey RS. Phospholipid-polymer hybrid nanoparticles mediated transfollicular delivery of Quercetin: prospective implement for the treatment of androgenic alopecia. Drug Dev Ind Pharm 2019; 45: 1-27.
[http://dx.doi.org/10.1080/03639045.2019.1652635]
[88]
Fernandes B, Silva R, Ribeiro A, et al. Improved poly (D,L-lactide) nanoparticles-based formulation for hair follicle targeting. Int J Cosmet Sci 2015; 37: 282-90.
[http://dx.doi.org/10.1111/ics.12197]
[89]
Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm 2009; 366: 170-84.
[http://dx.doi.org/10.1016/j.ijpharm.2008.10.003]
[90]
Hamishehkar H, Ghanbarzadeh S, Sepehran S, et al. Histological assessment of follicular delivery of flutamide by solid lipid nanoparticles: Potential tool for the treatment of androgenic alopecia. Drug Dev Ind Pharm 2016; 42: 846-53.
[http://dx.doi.org/10.3109/03639045.2015.1062896]
[91]
Loo CH, Basri M, Ismail R, et al. Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusion. Int J Nanomedicine 2013; 8: 13-22.
[http://dx.doi.org/10.2147/IJN.S35648]
[92]
Yazdani-Arazi SN, Ghanbarzadeh S, Adibkia K, et al. Histological evaluation of follicular delivery of arginine via nanostructured lipid carriers: a novel potential approach for the treatment of alopecia. Artif Cells Nanomed Biotechnol 2017; 45: 1379-87.
[http://dx.doi.org/10.1080/21691401.2016.1241794]
[93]
Wang W, Chen L, Huang X, Shao A. Preparation and characterization of minoxidil loaded nanostructured lipid carriers. AAPS PharmSciTech 2017; 18: 509-16.
[http://dx.doi.org/10.1208/s12249-016-0519-x]
[94]
Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011; 12: 62-76.
[http://dx.doi.org/10.1208/s12249-010-9563-0]
[95]
Shamma RN, Aburahma MH. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Int J Nanomedicine 2014; 9: 5449-60.
[http://dx.doi.org/10.2147/IJN.S73010]
[96]
Uprit S, Sahu RK, Roy A, Pare A. Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J 2013; 21: 379-85.
[http://dx.doi.org/10.1016/j.jsps.2012.11.005]
[97]
Ghasemiyeh P, Azadi A, Daneshamouz S. Cyproterone acetate-loaded nanostructured lipid carriers: effect of particle size on skin penetration and follicular targeting. Pharm Dev Technol 2019; 24: 812-23.
[http://dx.doi.org/10.1080/10837450.2019.1596133]
[98]
Cal K, Wosicka H. inventor; Gda Ski Uniwersytet Medyczny, assignee. Solid lipid nanoparticles of roxithromycin for hair loss or acne. European Patent EP2919756B1, 2018.
[99]
Walsh JF. inventor. Method and preparation for treating baldness. United States Patent US 20100209368A1, 2010.
[100]
Shah NA. inventor; Composition and related methods for treatment of pilosebaceous diseases. United State Patent US 2017/0027881 A1, 2017.
[101]
Rubin P. inventor; Xoma US LLC, assignee. Methods for treating acne. Europen Patent EP2794657B1, 2017.
[102]
Jingchun Y. inventor; Lunan Pharmaceutical Group Co. Ltd., assignee. Medication combination of containing finasteride and cyclodextrin or ramification. CN1294913C
[103]
Feng L, Asia S, Guo L, Hui H. inventor; Changsha Jingyi Pharmaceutical Technology Co. Ltd., assignee. Finasteride nano-liposome, gel and preparation method thereof. CN106361703A. 2017.
[104]
Pohlmann AR, Jornada DS, Nascimento LPD, Guterres SS. inventors; Biolab Sanus Farmaceutia Ltd. and Universidade Federal DoRia Grande Do Sul-UFRGS, assignees. Finasteride and minoxidil polymeric nonoparticle, its process of preparation, aoueous suspension containing the same, pharmaceutical composition, and its use.United States Patent US 2015/0216986 A1, 2015.
[105]
Tamarkin D, Gazal E, Keynan R, Eini M, Schuz D. inventor; Foamix Ltd., assignee.Compositions for the improved treatment of acne and related disorders. United State Patent US 20140121188A1, 2014.
[106]
Jun T, Dangguo W, Haitao G, Yuanming T. inventor; Jiangsu Huanghe Pharmaceutical Co., Ltd. assignee. Solid lipid nanoparticles of finasteride and preparation method thereof. CN101559038B, 2010.
[107]
Lili X, Qinghua C, Feng P, Lin C, Yan Z, Shuwu X. inventor; Shanghai Institute of Pharmaceutical Industry, assignee. Sustained release microsphere of nasteride and its analogue, preparation process and use thereof CN1965839B. CN1965839A, 2010.
[108]
Walsh JF. inventor; Method and preparation for treating baldness.United State Patent US 2010O2.09368A1 2010.
[109]
Dascalu A. inventor; Medidermis Ltd. (IL), assignee. Compositions for the treatment of pilosebaceous gland inflammations comprising aluminum fluoride. United State Patent US007452556B2. 2008.
[110]
Weidner M. inventor; Astion Inflammation ApS, assignee. Treatment of acne and other diseases. United State Patent US 20070225301A1. 2007.
[111]
Lionel B, Albert D. inventor; Davies Collison Cave, 1 Nicholson Street, Melbourne, VIC, 3000, assignee. Use of taurine or derivatives thereof for the treatment of alopecia. AU 2007229399 B2, 2006.
[112]
Liversidge G, Jenkins S. inventor; Elan Pharma International Limited, assignee. Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof. United State Patent US 20060204588A1, 2006.
[113]
Sanders RJ. inventor. Method of treating hair loss. United State Patent US6762193B1,. 2004.
[114]
Niazi S. inventor. Pharmaceutical composition for the treatment of alopecia. United States Patent US20020183297 A1,. 2002.
[115]
Waldstreicher J. inventor; Merck and Co Inc, assignee. Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one. United States Patent US5512555A,. 1996.
[116]
Rasmusson GH, and Reynolds GF. inventor; Merck Sharp and Dohme Corp, assignee. Methods of treating androgenic alopecia wth fnasteride [17-N-mono-substituted-carbamoyl-4-aza-5-androst-1-en-ones]. United States Patent US5567708A. 1996.
[117]
Benitez JE. inventor. Topcal treatment for acne. United States Patent US5505949A,. 1996.
[118]
Robinson HN, Martin NF. inventors; Towsend MS, Bloom L, assignees. Topical treatment of acne with cephalosporins. United State Patent USOO5409917A, 1995.
[119]
Robinson HN, Martin NF. inventors; Towsend MS, Bloom L, assignees. Topical treatment of acne with aminopenicillins. United State Patent USOOS260292A 1993.